193 related articles for article (PubMed ID: 2022919)
1. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.
Blankenstein T; Qin ZH; Uberla K; Müller W; Rosen H; Volk HD; Diamantstein T
J Exp Med; 1991 May; 173(5):1047-52. PubMed ID: 2022919
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
Hock H; Dorsch M; Kunzendorf U; Qin Z; Diamantstein T; Blankenstein T
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2774-8. PubMed ID: 8464888
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
[TBL] [Abstract][Full Text] [Related]
4. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4.
Li WQ; Diamantstein T; Blankenstein T
Mol Immunol; 1990 Dec; 27(12):1331-7. PubMed ID: 2274062
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell IL-6 gene expression is regulated by IL-1 alpha/beta and TNF alpha: proposed feedback mechanisms induced by the interaction of tumor cells and macrophages.
Evans R; Fong M; Fuller J; Kamdar S; Meyerhardt J; Strassmann G
J Leukoc Biol; 1992 Oct; 52(4):463-8. PubMed ID: 1402392
[TBL] [Abstract][Full Text] [Related]
6. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.
Qin Z; Blankenstein T
Cancer Res; 1995 Nov; 55(21):4747-51. PubMed ID: 7585497
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
Wright P; Zheng C; Moyana T; Xiang J
Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
Xiang J; Qi Y; Chen Y
Cancer Gene Ther; 1997; 4(6):353-8. PubMed ID: 9408605
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 7 induces CD4+ T cell-dependent tumor rejection.
Hock H; Dorsch M; Diamantstein T; Blankenstein T
J Exp Med; 1991 Dec; 174(6):1291-8. PubMed ID: 1683890
[TBL] [Abstract][Full Text] [Related]
11. Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA.
Han SK; Brody SL; Crystal RG
Am J Respir Cell Mol Biol; 1994 Sep; 11(3):270-8. PubMed ID: 8086165
[TBL] [Abstract][Full Text] [Related]
12. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer.
Cao G; Kuriyama S; Du P; Sakamoto T; Kong X; Masui K; Qi Z
Gastroenterology; 1997 Feb; 112(2):501-10. PubMed ID: 9024304
[TBL] [Abstract][Full Text] [Related]
13. Treatment of established tumor is associated with ICAM-1 upregulation and reversed by CD8 depletion in a tumor necrosis factor-alpha gene transfected mouse mammary tumor.
Matory YL; Dorfman DM; Wu L; Chen M; Goedegebuure P; Eberlein TJ
Pathobiology; 1999; 67(4):186-95. PubMed ID: 10738180
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice.
Wright P; Braun R; Babiuk L; Littel-van den Hurk SD; Moyana T; Zheng C; Chen Y; Xiang J
Cancer Biother Radiopharm; 1999 Feb; 14(1):49-57. PubMed ID: 10850287
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
16. Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule.
Hoogenboom HR; Raus JC; Volckaert G
Biochim Biophys Acta; 1991 Jun; 1096(4):345-54. PubMed ID: 2065106
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor is required for the priming of peritoneal macrophages by trehalose dimycolate.
Oswald IP; Dozois CM; Fournout S; Petit JF; Lemaire G
Eur Cytokine Netw; 1999 Dec; 10(4):533-40. PubMed ID: 10586120
[TBL] [Abstract][Full Text] [Related]
18. Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression.
Dorsch M; Hock H; Kunzendorf U; Diamantstein T; Blankenstein T
Eur J Immunol; 1993 Jan; 23(1):186-90. PubMed ID: 8419170
[TBL] [Abstract][Full Text] [Related]
19. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha is an autocrine growth regulator during macrophage differentiation.
Witsell AL; Schook LB
Proc Natl Acad Sci U S A; 1992 May; 89(10):4754-8. PubMed ID: 1374912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
